Locations:
Search IconSearch
May 9, 2017/Cancer

Novel Convection-Enhanced Delivery Device Wins FDA Clearance

Path cleared for use of Cleveland Multiport Catheter in IND-based trials

17-NEU-1159-Vogelbaum-650×450

A novel convection-enhanced delivery (CED) device developed under the leadership of Cleveland Clinic neurosurgeon Michael Vogelbaum, MD, PhD, has received FDA 510(k) clearance as a therapeutic delivery device.

Advertisement

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

The device, known as the Cleveland Multiport Catheter (CMC), features four microcatheters (see photo above) and was designed for higher-volume drug distribution to glioma tumors and tumor-infiltrated brain tissue.

FDA clearance was granted in late March 2017. While no therapeutic has yet received FDA approval for direct delivery into brain parenchyma, “this clearance of the CMC is important to developers of drugs and biologics for direct delivery to the CNS, as they are looking to use an FDA-cleared catheter for their IND-based clinical trials,” explains Dr. Vogelbaum, Associate Director of Cleveland Clinic’s Rose Ella Burkhardt Brain Tumor and Neuro-Oncology Center and Professor of Neurosurgery at Cleveland Clinic Lerner College of Medicine.

CMC essentials and background

The rationale and history behind the CMC are detailed in a previous Consult QD post. Dr. Vogelbaum and colleagues are accumulating experience with the CMC through a first-in-human clinical trial of the catheter at Cleveland Clinic. Since the first patient was treated in December 2014, 11 patients with glioma have completed treatment with the device under the trial’s investigational protocol.

For these procedures, two CMC microcatheters have been placed in each patient using conventional neurosurgical stereotactic techniques. Topotecan is infused along with a gadolinium tracer into tumor and/or tumor-infiltrated brain tissue via the microcatheters for up to 96 hours. Intermittent MRI monitoring has shown that the infusions have produced widespread distribution of drug and tracer into tumor-infiltrated brain.

Advertisement

“The extent of brain tissue covered and the reliability of the technique in these patients to date are largely unparalleled by past experience with other CED devices,” notes Dr. Vogelbaum.

Additional investigations are continuing to determine optimal parameters for use of the CMC in solid tumors and in tumor-infiltrated brain. Use for treatment of other conditions affecting the brain and CNS is also being explored.

Disclosure: Dr. Vogelbaum is an inventor and patent holder of the Cleveland Multiport Catheter (CMC). He is also founder and Chief Medical Officer of Infuseon Therapeutics Inc, which leads clinical development of the CMC. He holds equity and royalty interests in these entities. His participation in the CMC’s clinical development is covered by a Cleveland Clinic-approved conflict management plan.

Advertisement

Related Articles

Interactive culinary medicine class
November 11, 2024/Cancer/Innovations
Integrative Oncology Improves Outcomes and Quality of Life

Combining mind, body and lifestyle practices in alignment with conventional cancer treatment

Pregnant woman
November 6, 2024/Cancer/News & Insight
Large Retrospective Study Finds Pregnancy Safe Among Young BRCA Carriers

Pregnancy did not appear to increase the risk of recurrence in patients or complications in their children

Young patient with cancer
October 25, 2024/Cancer/News & Insight
Multidisciplinary Care Model Supports Young People with Cancer

Integrated program addresses growing need for comprehensive cancer care among adolescents, young adults and adults under 50 with early onset cancers

Hurthle cell carcinoma
October 24, 2024/Cancer/News & Insight
Researchers Uncover Clues to Treating Rare Thyroid Cancer

Studies find mTOR inhibitor may play key role in treating Hurthle cell carcinoma

DNA
October 10, 2024/Cancer/Research
Blocking YES1 Protein Resensitizes Triple-Negative Breast Cancer to Treatment

Obstructing key protein allows for increased treatment uptake for taxane chemotherapy

Plan of care meeting
October 4, 2024/Cancer/Radiation Oncology
Five Years of Parallel Prospective Plan of Care Reviews

Radiation oncology department finds weekly plan of care meetings have multiple benefits

Ad